Lack of response in severe pneumocystis pneumonia to combined caspofungin and clindamycin treatment: a case report.
- Author:
Zhang YAO
1
;
Zhang HUA
;
Xu JUN
;
Wu CHAN
;
Ma XIAO-JUN
Author Information
1. Department of Infectious Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.
- Publication Type:Case Reports
- MeSH:
AIDS-Related Opportunistic Infections;
drug therapy;
Adult;
Anti-Bacterial Agents;
administration & dosage;
Antifungal Agents;
administration & dosage;
Clindamycin;
administration & dosage;
Drug Therapy, Combination;
Echinocandins;
administration & dosage;
Humans;
Lipopeptides;
Male;
Pneumonia, Pneumocystis;
drug therapy
- From:
Chinese Medical Sciences Journal
2011;26(4):246-248
- CountryChina
- Language:English
-
Abstract:
Pneumocystis pneumonia (PCP) is among the most common opportunistic infections in patients with acquired immune deficiency syndrome (AIDS). Although trimethoprim-sulfamethoxazole (TMP-SMX) is the first line therapy for that condition given its efficacy, approximately one third of patients experienced dose-limiting toxicity. For cases of severe to moderate PCP, if TMP-SMX treatment fails or is contraindicated, primaquine combined with clindamycin or intravenous pentamidine is recommended as second line therapy. However, both primaquine and pentamidine are associated with severe adverse reactions and often unavailable at hospitals in China.As a result, other treatment options have been explored. Caspofungin, an echinocandin, has broad antifungal activity against a wide range of fungi including Candida and Aspergillus species. Cases of PCP patients treated with caspofungin have been reported, although conflicting conclusions have been arrived at. In addition, the use of caspofungin and clindamycin as the first line therapy for severe PCP in AIDS patients has not been reported yet. This article described an AIDS case with severe PCP, treated with the combination of caspofungin and clindamycin.
